Swiss remote diagnostic monitoring company LifeWatch has secured a clearance from the FDA for its wireless, patch-based vital signs monitoring system. It's expected to be used first in medical facilities such as hospitals and nursing homes, but eventually the company expects to target the ambulatory care market as well.
The Vital Signs Patch is worn on a patient's upper chest. In adult patients in a clinical environment, it offers continuous, noninvasive monitoring of ECG, heart rate, respiration rate, surface temperature, arterial blood oxygen saturation and body position. It will be available in two versions, with and without the ECG component.
No comments:
Post a Comment